- Home
- FOLD vs EPAC Comparison
FOLD vs EPAC Comparison
Compare FOLD & EPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- EPAC
- Stock Information
- Founded
- FOLD 2002
- EPAC 1910
- Country
- FOLD United States
- EPAC United States
- Employees
- FOLD N/A
- EPAC N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- EPAC Industrial Machinery/Components
- Sector
- FOLD Health Care
- EPAC Technology
- Exchange
- FOLD Nasdaq
- EPAC Nasdaq
- Market Cap
- FOLD 2.5B
- EPAC 2.2B
- IPO Year
- FOLD 2007
- EPAC N/A
- Fundamental
- Price
- FOLD $8.15
- EPAC $39.62
- Analyst Decision
- FOLD Strong Buy
- EPAC Strong Buy
- Analyst Count
- FOLD 9
- EPAC 2
- Target Price
- FOLD $26.44
- EPAC $50.50
- AVG Volume (30 Days)
- FOLD 5.8M
- EPAC 387.4K
- Earning Date
- FOLD 11-05-2025
- EPAC 10-15-2025
- Dividend Yield
- FOLD N/A
- EPAC 0.10%
- EPS Growth
- FOLD N/A
- EPAC 7.49
- EPS
- FOLD N/A
- EPAC 1.63
- Revenue
- FOLD $571,160,000.00
- EPAC $608,099,000.00
- Revenue This Year
- FOLD $20.98
- EPAC $6.25
- Revenue Next Year
- FOLD $20.74
- EPAC $5.39
- P/E Ratio
- FOLD N/A
- EPAC $24.43
- Revenue Growth
- FOLD 25.35
- EPAC 2.82
- 52 Week Low
- FOLD $5.51
- EPAC $36.51
- 52 Week High
- FOLD $12.65
- EPAC $51.91
- Technical
- Relative Strength Index (RSI)
- FOLD 56.40
- EPAC 40.05
- Support Level
- FOLD $7.69
- EPAC $39.61
- Resistance Level
- FOLD $8.59
- EPAC $41.88
- Average True Range (ATR)
- FOLD 0.37
- EPAC 0.86
- MACD
- FOLD -0.05
- EPAC -0.14
- Stochastic Oscillator
- FOLD 54.44
- EPAC 3.24
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
About EPAC Enerpac Tool Group Corp.
Enerpac Tool Group Corp provides high-precision tools, controlled-force products, and solutions for precise heavy lifting. The company has one reportable segment, the Industrial Tools & Services (IT&S) Segment. The IT&S segment is engaged in the design, manufacture, and distribution of branded hydraulic and mechanical tools and in providing services and tool rental to the refinery/petrochemical; general industrial; industrial maintenance, repair, and operations (MRO); machining & manufacturing; power generation; infrastructure; mining; and other markets. Geographically, the company has operations in Algeria, Australia, Brazil, France, Germany, Kazakhstan, India, Italy, Japan, Norway, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Spain, and the United Arab Emirates.